Browsing Tag
Merck & Co.
29 posts
Merck’s $6.7bn Terns deal moves closer as TERN trades near offer price
Merck cleared a deal hurdle. TERN-701 now has to show whether one CML asset can justify a $6.7bn oncology bet.
April 26, 2026
Does CADENCE confirm a scalable pathway for treating complex pulmonary vascular disease beyond pulmonary arterial hypertension?
WINREVAIR’s Phase 2 data signals expansion beyond pulmonary arterial hypertension. Find out what this means for Merck & Co., Inc. and the market.
March 31, 2026
Is Merck & Co., Inc. embedding artificial intelligence at the core of its oncology strategy through Tempus AI integration?
Merck expands its Tempus AI collaboration to embed artificial intelligence into oncology research. What this means for MRK, TEM, and precision medicine.
March 3, 2026
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
December 29, 2025
PADCEV plus Keytruda shows survival benefit in muscle-invasive bladder cancer regardless of cisplatin eligibility
PADCEV plus Keytruda shows significant survival benefit in cisplatin-eligible muscle-invasive bladder cancer. Find out what the EV-304 data means for treatment standards.
December 19, 2025
Anixa Biosciences (NASDAQ: ANIX) moves forward as Phase 1 breast cancer vaccine data clear safety and immune hurdles
Anixa Biosciences’ breast cancer vaccine met Phase 1 safety and immune response targets. Find out how Keytruda combinations could transform care.
December 12, 2025
CD388 in focus as Merck announces $9.2bn deal for Cidara Therapeutics (NASDAQ: CDTX)
Merck is acquiring Cidara Therapeutics for $9.2B to expand into long-acting antivirals. Find out what makes CD388 a potential flu game-changer.
November 19, 2025
Merck announces acquisition of Cidara Therapeutics in bid to strengthen its infectious disease portfolio
Find out how Merck’s acquisition of Cidara Therapeutics could reshape long-acting influenza prevention and expand the company’s infectious disease pipeline.
November 14, 2025
Merck’s enlicitide slashes LDL-C by 55.8%: Could this daily pill replace PCSK9 injections?
Merck’s enlicitide cuts LDL-C by over 55% in Phase 3 trial. Could it become the first oral PCSK9 inhibitor to transform ASCVD treatment?
November 9, 2025
Is Merck building the next great cardiometabolic franchise? A closer look at WINREVAIR, enlicitide and Ohtuvayre
See how Merck is building a cardiometabolic growth engine with WINREVAIR, enlicitide and Ohtuvayre—and what it means for investors.
October 31, 2025